Literature DB >> 9505981

Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial.

M D Freedman1, H J Schwartz, R Roby, S Fleisher.   

Abstract

Chronicity and high therapeutic cost prompted this study to determine a cost-effective and efficacious regimen in treating narcotic-induced constipation. The efficacy of lactulose was compared with polyethylene glycol 3350/electrolyte solution for relief of methadone-induced constipation. This was a randomized, triple cross-over after control run-in (no treatment) study conducted at a methadone maintenance program in Baltimore, Maryland in 57 patients who are affected by opiate-induced constipation. The study was measured by self-reported frequencies, consistency, and ease of defecation during a 1 week run-in control period, followed by 3 treatment phases of 2 weeks each. Polyethylene glycol 3350/electrolyte solution and lactulose produced more "nonhard" stools than the placebo (P < 0.01) and control (P < 0.003). Polyethylene glycol 3350/electrolyte solution produced the loosest stool (P < 0.0001) compared with the control, whereas lactulose had the most adverse effects. There were no significant differences in reducing hard stool formation in either experimental group, but both were better than having nothing or just the placebo. Polyethylene glycol/electrolyte solution resulted in the loosest (diarrheal) stool. It is also likely that polyethylene glycol/electrolyte solution is the most cost effective.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9505981     DOI: 10.1002/j.1552-4604.1997.tb04264.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  25 in total

1.  Lack of objective evidence of efficacy of laxatives in chronic constipation.

Authors:  Michael P Jones; Nicholas J Talley; Guy Nuyts; Dominique Dubois
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

2.  Opioid-induced bowel dysfunction.

Authors:  Howard Y Chang; Anthony J Lembo
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

Review 3.  Evolving paradigms in the treatment of opioid-induced bowel dysfunction.

Authors:  Jakob Lykke Poulsen; Christina Brock; Anne Estrup Olesen; Matias Nilsson; Asbjørn Mohr Drewes
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 4.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

Review 5.  Management of chronic constipation in the elderly.

Authors:  Paul F Gallagher; Denis O'Mahony; Eamonn M M Quigley
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  All Roads Lead to Rome: Update on Rome III Criteria and New Treatment Options.

Authors:  David Q Shih; Lola Y Kwan
Journal:  Gastroenterol Rep       Date:  2007       Impact factor: 3.651

Review 7.  American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced Constipation.

Authors:  Brian Hanson; Shazia Mehmood Siddique; Yolanda Scarlett; Shahnaz Sultan
Journal:  Gastroenterology       Date:  2018-10-16       Impact factor: 22.682

Review 8.  Management of chronic constipation in patients with diabetes mellitus.

Authors:  V G M Prasad; Philip Abraham
Journal:  Indian J Gastroenterol       Date:  2016-12-17

Review 9.  Appropriate use of laxatives in the management of constipation.

Authors:  Arnold Wald
Journal:  Curr Gastroenterol Rep       Date:  2007-10

Review 10.  New developments in the treatment of opioid-induced gastrointestinal symptoms.

Authors:  Jasper Pannemans; Tim Vanuytsel; Jan Tack
Journal:  United European Gastroenterol J       Date:  2018-08-27       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.